Free tool
FAERS Monitor: Advil Cold and Sinus
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019771 or its brand name (Advil Cold and Sinus, Ibuprofen, Pseudoephedrine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,326
Serious
391
29% of reports
Hospitalization
120
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective317
- nausea66
- headache62
- dizziness59
- condition aggravated52
- insomnia52
- arthralgia47
- fatigue46
- dyspnoea45
- off label use43
- joint swelling40
- malaise40
- drug hypersensitivity39
- pain39
- product use in unapproved indication39
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 14 |
| 2005 | 16 |
| 2006 | 18 |
| 2007 | 8 |
| 2008 | 9 |
| 2009 | 9 |
| 2010 | 97 |
| 2011 | 109 |
| 2012 | 81 |
| 2013 | 69 |
| 2014 | 99 |
| 2015 | 95 |
| 2016 | 106 |
| 2017 | 97 |
| 2018 | 82 |
| 2019 | 95 |
| 2020 | 69 |
| 2021 | 65 |
| 2022 | 55 |
| 2023 | 41 |
| 2024 | 44 |
| 2025 | 32 |
| 2026 | 16 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,833 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| joint swellingSignal | 40 | 5.3 | 3.9 | 134 |
| drug ineffectiveSignal | 317 | 3.8 | 3.5 | 700 |
| drug hypersensitivitySignal | 39 | 3.2 | 2.3 | 57 |
| insomniaSignal | 52 | 3.1 | 2.4 | 73 |
| condition aggravatedSignal | 52 | 2.7 | 2.1 | 55 |
| product use in unapproved indicationSignal | 39 | 2.5 | 1.8 | 34 |
| dizziness | 59 | 1.9 | 1.5 | 24 |
| arthralgia | 47 | 1.8 | 1.4 | 16 |
| headache | 62 | 1.6 | 1.2 | 13 |
| malaise | 40 | 1.4 | 1.1 | 5 |
| nausea | 66 | 1.3 | 1.0 | 5 |
| dyspnoea | 45 | 1.3 | 0.9 | 2 |
| pain | 39 | 1.0 | 0.7 | 0 |
| fatigue | 46 | 0.9 | 0.7 | 0 |
| off label use | 43 | 0.8 | 0.6 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.